Next generation oncology drug development: opportunities and challenges

[1]  S. Steinberg,et al.  Designing Phase 0 Cancer Clinical Trials , 2008, Clinical Cancer Research.

[2]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Ascierto,et al.  EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results , 2008 .

[4]  R. Benjamin,et al.  Selection of response criteria for clinical trials of sarcoma treatment. , 2008, The oncologist.

[5]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Kudoh,et al.  Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) , 2008, British Journal of Cancer.

[7]  Edward S. Kim,et al.  Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib , 2007, Clinical Cancer Research.

[8]  Hui Peng,et al.  Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. , 2007, Current medicinal chemistry.

[9]  S. Steinberg,et al.  Compressing drug development timelines in oncology using phase '0' trials , 2007, Nature Reviews Cancer.

[10]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[11]  D. Haber,et al.  A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. , 2006, Cancer cell.

[12]  S. Thongprasert,et al.  Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  J. Dancey,et al.  Strategies for optimizing combinations of molecularly targeted anticancer agents , 2006, Nature Reviews Drug Discovery.

[14]  A. Joe,et al.  Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.

[15]  J. Doroshow,et al.  Drug development in oncology: classical cytotoxics and molecularly targeted agents. , 2006, British journal of clinical pharmacology.

[16]  C. Antonescu,et al.  Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Burger,et al.  Bevacizumab in patients with advanced platinum-resistant ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Seymour,et al.  Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. , 2006, Clinical lung cancer.

[20]  R. Simon,et al.  Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients , 2005, Clinical Cancer Research.

[21]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[22]  J. Collins.  Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Richard Simon,et al.  Evaluation of randomized discontinuation design. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Rosner,et al.  Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Edward S. Kim,et al.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Klein,et al.  Targeted therapy: wave of the future. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[29]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[30]  H. Rugo.  Bevacizumab in the treatment of breast cancer: rationale and current data. , 2004, The oncologist.

[31]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[32]  Young Suk Park,et al.  Measuring response in solid tumors: comparison of RECIST and WHO response criteria. , 2003, Japanese journal of clinical oncology.

[33]  B. Druker,et al.  Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib , 2003, Pharmacological Reviews.

[34]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[35]  Andrew W. Millar,et al.  Rethinking clinical trials for cytostatic drugs , 2003, Nature Reviews Cancer.

[36]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Elizabeth Fox,et al.  Clinical trial design for target-based therapy. , 2002, The oncologist.

[38]  N. Cascinelli,et al.  Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.

[39]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[41]  N. Lydon,et al.  Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. , 1997, Blood cells, molecules & diseases.

[42]  M. Abrahamowicz,et al.  Randomized discontinuation trials: utility and efficiency. , 1993, Journal of clinical epidemiology.

[43]  W. Amery,et al.  A Clinical Trial Design Avoiding Undue Placebo Treatment , 1975, Journal of clinical pharmacology.

[44]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.